PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia Mar 13 Written by Allison Talbot Allison Talbot Previous Previous PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia Mar 13 Written by Allison Talbot Allison Talbot
